Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 2Thyroid Cancer, Papillary 1Neoplasm Metastasis 1Adenocarcinoma, Follicular 1

Interventions

Specimen Handling 40Biopsy 39Magnetic Resonance Spectroscopy 31Cyclophosphamide 21aldesleukin 20fludarabine 16fludarabine phosphate 13Leucovorin 12Fluorouracil 12Interleukin-2 11Paclitaxel 9Melphalan 9Oxaliplatin 8trastuzumab deruxtecan 7Irinotecan 7X-Rays 6Taxes 6Nivolumab 6olaparib 5Ipilimumab 5CTLA-4 Antigen 5trametinib 4Neoadjuvant Therapy 4Floxuridine 4Doxorubicin 4Chemotherapy, Adjuvant 4Carboplatin 4veliparib 3talazoparib 3pembrolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasm Metastasis × Iodine-124 × Clear all
NCT03841617 2026-06-05

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡